Prof. Dr. med. et phil. nat. Markus Jörger
Oberarzt Onkologie/Hämatologie
Mitarbeiter Wissenschaftliche Module CTU (Klinische Pharmakologie)
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
27.06.2014Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
27.06.2014Int J Cancer 2014; 136:730-9
Froehlich Tanja K, Amstutz Ursula, Aebi Stefan, Jörger Markus, Largiadèr Carlo R
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
29.05.2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
29.05.2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Jörger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
11.03.2014Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
11.03.2014Eur J Clin Pharmacol 2014; 70:719-25
Jörger Markus, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem Stefan, Thürlimann Beat, Cerny Thomas
[Role of individualized dosing in oncology: are we there yet?]
Jörger M. [Role of individualized dosing in oncology: are we there yet?]. Praxis (Bern 1994) 2013; 103:33-9.
31.12.2013[Role of individualized dosing in oncology: are we there yet?]
31.12.2013Praxis (Bern 1994) 2013; 103:33-9
Jörger Markus
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
29.10.2013Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
29.10.2013Cancer Chemother Pharmacol 2013; 73:113-24
Jörger Markus, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz Felicitas, Cerny Thomas, Schellens J H M, Gillessen Sommer Silke
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Büchel B, Sistonen J, Jörger M, Aebi Y, Schürch S, Largiadèr C. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
01.08.2013Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
01.08.2013Clin Chem Lab Med 2013; 51:1681-8
Büchel Barbara, Sistonen Johanna, Jörger Markus, Aebi Yolanda, Schürch Stefan, Largiadèr Carlo R
Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
Früh M, Besrour H, Gillessen Sommer S, Jörger M, Hitz F, Savidan A, Cerny T, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. Chemotherapy 2013; 59:42-50.
02.07.2013Management of elderly patients with advanced non-small cell lung cancer: a single-center experience
02.07.2013Chemotherapy 2013; 59:42-50
Früh Martin, Besrour H, Gillessen Sommer Silke, Jörger Markus, Hitz Felicitas, Savidan A, Cerny Thomas, Ess S
Chemotherapy regimens in early breast cancer: major controversies and future outlook
Jörger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
01.02.2013Chemotherapy regimens in early breast cancer: major controversies and future outlook
01.02.2013Expert Rev Anticancer Ther 2013; 13:165-78
Jörger Markus, Thürlimann Beat
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
01.09.2012Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
01.09.2012Clin Pharmacokinet 2012; 51:607-17
Jörger Markus, Kraff Stefanie, Huitema Alwin D R, Feiss Gary, Moritz Berta, Schellens Jan H M, Beijnen Jos H, Jaehde Ulrich
Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Jörger M, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann B, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
24.08.2012Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
24.08.2012J Geriatr Oncol 2012; 4:39-47
Jörger Markus, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann Beat, Ess S
Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis
Jörger M, Wilkins J, Fagagnini S, Baldinger R, Brenneisen R, Schneider U, Goldman B, Weber M. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett 2012; 6:102-8.
01.06.2012Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis
01.06.2012Drug Metab Lett 2012; 6:102-8
Jörger Markus, Wilkins Justin, Fagagnini Stefania, Baldinger Reto, Brenneisen Rudolf, Schneider Ursula, Goldman Bea, Weber Markus
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
Jörger M, Huitema A, Illerhaus G, Ferreri A. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012; 53:1867-75.
21.05.2012Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
21.05.2012Leuk Lymphoma 2012; 53:1867-75
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Jörger M, ess s, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
11.04.2012A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
11.04.2012Swiss Med Wkly 2012; 142:w13571
Jörger Markus, ess silvia, Dehler Silvia, Savidan Anita, Bouchardy Christine, Frick Harald, Konzelmann Isabelle, Thürlimann Beat
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Hochstrasser A, Benz G, Jörger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
23.02.2012Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
23.02.2012Chemotherapy 2012; 58:84-88
Hochstrasser Andreas, Benz Gabriel, Jörger Markus, Templeton Arnoud, Brutsche Martin, Früh Martin
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
01.02.2012Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
01.02.2012Br J Clin Pharmacol 2012; 73:240-7
Jörger Markus, Ferreri Andrés J M, Krähenbühl Stephan, Schellens Jan H M, Cerny Thomas, Zucca Emanuele, Huitema Alwin D R
Covariate pharmacokinetic model building in oncology and its potential clinical relevance
Jörger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14:119-32.
25.01.2012Covariate pharmacokinetic model building in oncology and its potential clinical relevance
25.01.2012AAPS J 2012; 14:119-32
Jörger Markus
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
04.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
04.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Diagnostic and prognostic use of bone turnover markers
Jörger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012; 192:197-223.
01.01.2012Diagnostic and prognostic use of bone turnover markers
01.01.2012Recent Results Cancer Res 2012; 192:197-223
Jörger Markus, Huober Jens
Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities
Büchel B, Jörger M, Schürch S, Largiader C. Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities. 2012; Clinical Chemistry Annual Conference
01.01.2012Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities
01.01.20122012; Clinical Chemistry Annual Conference
Büchel B, Jörger Markus, Schürch S, Largiader CR
Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy
Büchel B, Jörger M, Schürch S, Largiader C. Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy. Biomed Chromatogr 2012
01.01.2012Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy
01.01.2012Biomed Chromatogr 2012
Büchel B, Jörger Markus, Schürch S, Largiader CR